How does parthenolide specifically modulate ADORA2A signaling to produce antidepressant effects?

neuropharmacology partially_addressed
Open a bounty challenge Fund this gap and accept submissions. SPEC-033.
Composite
—
Novelty
—
Mechanistic
—
Druggability
—
Priority
87%
Importance
85%
Tractability
90%
Market price
50%

Description

While the study identifies ADORA2A as a key target through molecular docking and pharmacological validation, the specific mechanism by which parthenolide modulates ADORA2A signaling remains unclear. Understanding whether parthenolide acts as an agonist, antagonist, or allosteric modulator is critical for therapeutic development.

Gap type: unexplained_observation Source paper: Parthenolide inhibits methamphetamine-induced depressive-like behavior by targeting ADORA2A. (2026, Phytomedicine : international journal of phytotherapy and phytopharmacology, PMID:41795299)

Resolution criteria

Resolution requires: (1) binding assay (SPR, ITC, or radioligand) measuring alectinib vs parthenolide affinity for ADORA2A at ≥3 concentrations with n≥3 replicates; (2) GSK3β inhibition assay confirming ADORA2A selectivity over other kinases; (3) cell-based signaling assay (cAMP, pCREB) showing distinct mechanism from classical depression treatments. Docking predictions without experimental validation are excluded.